Share on StockTwits

Shares of MannKind (NASDAQ:MNKD) have received a consensus recommendation of “Hold” from the nine analysts that are covering the company, ARN reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $9.36.

Shares of MannKind (NASDAQ:MNKD) traded up 2.65% during mid-day trading on Wednesday, hitting $7.5343. 4,252,862 shares of the company’s stock traded hands. MannKind has a 52-week low of $3.80 and a 52-week high of $11.48. The stock has a 50-day moving average of $8.50 and a 200-day moving average of $7.60. The company’s market cap is $2.901 billion. MannKind also was the recipient of a significant increase in short interest in August. As of August 15th, there was short interest totalling 77,343,842 shares, an increase of 6.6% from the July 31st total of 72,584,807 shares. Based on an average daily volume of 17,109,430 shares, the days-to-cover ratio is currently 4.5 days. Currently, 31.0% of the shares of the company are short sold.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.19) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.07. During the same quarter last year, the company posted ($0.16) earnings per share. On average, analysts predict that MannKind will post $-0.38 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Jefferies Group initiated coverage on shares of MannKind in a research note on Wednesday. They set a “buy” rating and a $10.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of MannKind in a research note on Wednesday, August 13th. They now have a $7.75 price target on the stock. Finally, analysts at RBC Capital cut their price target on shares of MannKind from $16.00 to $13.00 in a research note on Tuesday, August 12th. They now have an “outperform” rating on the stock.

MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.

Receive News & Ratings for MannKind Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Co and related companies with Analyst Ratings Network's FREE daily email newsletter.